Vinita given the settlement, is it fair to assume that in Q4 you have sold significantly more Mirabegron compared to Q3?
And this third player who has settled with Astellas, have they already entered the market?
Questions across 6 calls
Bino Pathiparampil
Firm not listed in source transcripts
Lupin Limited
Just a follow up on Mirabegron settlement. From your notes, I see that you have taken a provision of USD 15 million, whereas the total pay-out is USD 90 million. So why only USD 15 million provision?
Now that we have a license in place, is there room to improve our Mirabegron market share? Because I believe we were selling much lower quantity than the other generic competitor. Is there a chance to equalize this?
Just wanted to follow-up on your GLP strategy. Globally you said '26 it starts, and could you give us some sense of when the markets open up globally, not just the US for the Semaglutides, Tirzepatides, et cetera, especially semi - regulated markets et cetera?
And you have a strategy in place to be in the first wave of launches in these countries?
Hi, Good morning, and good afternoon. Vinita, first on Spiriva, can we assume that an authorized generic is now not going to come or is it still a risk?
And in Myrbetriq, you launched only the 25 mg and not the 50 mg. What was the reason for that?
Hi. Can you hear me?
Okay. Good morning and evening. A couple of questions on products. Vinita, do you still expect Pegfilgrastim to come in FY '25?
Good morning and good evening. Hi, Vinita just a follow-up on Spiriva, you had mentioned earlier that you're seeing a substitution rate of 25%. How is this defined? What does that mean?
Okay. And how, one bottle or one canister, however you call it, how long does it typically last for a patient? One month, two months?